Vertex Pharmaceuticals IncorporatedVRTXNASDAQ
Loading
A large-scale business, with exceptional profitability priced at a premium.
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.
Comprehensive financial statement data for deep analysis
| Metric | Dec 21 | Dec 22 | Dec 23 | Dec 24 | Dec 25 |
|---|---|---|---|---|---|
| Return on Equity | - | - | - | - | - |
| Return on Invested Capital | - | - | - | - | - |
| Gross Margin | 88.1% | 87.9%↓0.2% | 87.2%↓0.8% | 86.1%↓1.3% | 85.0%↓1.3% |
| Operating Margin | 36.7% | 48.2%↑31.3% | 38.8%↓19.5% | -2.1%↓105.4% | 39.4%↑1965.6% |
| Net Margin | 30.9% | 37.2%↑20.3% | 36.7%↓1.4% | -4.9%↓113.3% | 32.7%↑773.6% |
| Earnings Yield | - | - | - | - | - |